GleamWall
中文EN

VYCO VYCOR MEDICAL INC

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1424768 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-10.2%
TTM net income YoY-289.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR6.3%
Net income 3-yr CAGR—

Margins

Gross margin82.4%
Operating margin2.5%
Net margin-3.8%
FCF margin—
EBITDA margin6.0%

Returns

ROE—
ROA-6.7%
ROIC (approx.)—
Asset turnover1.79x

Leverage & solvency

Liabilities / assets557.3%
Debt / equity—
Current ratio0.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.18x
Accruals ratio-21.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.86M$1.59M
Cost of revenue$302,293$166,809
Gross profit$1.56M$1.42M
R&D expense$9,963$15,325
SG&A expense$1.46M$1.36M
Operating income$33,900-$9,145
Pretax income-$70,190-$106,951
Net income-$72,426-$107,200
EBITDA$93,421$50,376
EPS (basic)-0.01-0.01
EPS (diluted)-0.01-0.01
Weighted avg. shares (diluted)33.37M32.88M
Balance sheet
Cash & equivalents$86,982$105,648
Receivables$218,891$245,260
Inventory$159,202$146,084
Current assets$563,422$619,614
PP&E, net$133,936$192,693
Total assets$830,420$998,117
Current liabilities$4.78M$4.50M
Total liabilities$4.92M$4.69M
Shareholders' equity-$4.09M-$3.69M
Shares outstanding33.37M33.37M
Cash flow statement
Operating cash flow-$13,471$60,110
Capital expenditure$5,224$5,366
Free cash flow-$18,695$54,744
Investing cash flow-$4,383-$4,199
Financing cash flow-$812-$7,554
Depreciation & amortization$59,521$59,521
Stock-based compensation$48,838$26,783

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.